GR3029582T3 - Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) - Google Patents

Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B)

Info

Publication number
GR3029582T3
GR3029582T3 GR990400666T GR990400666T GR3029582T3 GR 3029582 T3 GR3029582 T3 GR 3029582T3 GR 990400666 T GR990400666 T GR 990400666T GR 990400666 T GR990400666 T GR 990400666T GR 3029582 T3 GR3029582 T3 GR 3029582T3
Authority
GR
Greece
Prior art keywords
hepatitis
surface antigen
hep
virus
obtaining recombinant
Prior art date
Application number
GR990400666T
Other languages
English (en)
Inventor
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Garcia Manuel Palou
Escobar Giuvel Fontirrochi
Galvez Marcelo Nazabal
Griego Marta De Jesus Gonzalez
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Juli Padron
Albajes Victoria Ramirez
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Martinez Luis Saturnin Herrera
Cano Carlos Antonio Duarte
Suarez Lilia Luisa Perez
Suarez Jose San Rafael Garcia
La Riva De La Riva Gustavo De
Avila Ramon Alexis Santiago
Zorilla Filiberto Rosendo Ayon
Meireles Rolando Paez
Fierro Alberto Agraz
Betancourt Raul E Diaz
Maya Yair Quinones
Original Assignee
Cigb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cigb filed Critical Cigb
Publication of GR3029582T3 publication Critical patent/GR3029582T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
GR990400666T 1990-10-08 1999-03-04 Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) GR3029582T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal

Publications (1)

Publication Number Publication Date
GR3029582T3 true GR3029582T3 (en) 1999-06-30

Family

ID=5459466

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400666T GR3029582T3 (en) 1990-10-08 1999-03-04 Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B)

Country Status (9)

Country Link
EP (2) EP0480525B1 (el)
JP (2) JP3189212B2 (el)
AT (2) ATE175445T1 (el)
AU (1) AU649482B2 (el)
CU (1) CU22290A1 (el)
DE (2) DE69133525T8 (el)
DK (2) DK0480525T3 (el)
ES (2) ES2264183T3 (el)
GR (1) GR3029582T3 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU95109861A (ru) * 1994-06-09 1997-06-10 Сентро Де Инженьериа Генетика И Биотекнологиа (Cu) Рекомбинантный фрагмент антитела, применение scfv, применение фрагмента антитела или пептида, способ получения scfv
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (en) * 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
JP6981992B2 (ja) 2016-03-31 2021-12-17 セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア Ｂ型肝炎ウイルスの表面及び核内抗原を含む医薬組成物
KR102630293B1 (ko) * 2021-06-21 2024-01-29 선지호 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
JPH0576370A (ja) 1993-03-30
EP0864649B1 (en) 2006-04-26
DE69133525T2 (de) 2006-11-23
EP0864649A2 (en) 1998-09-16
CU22290A1 (es) 1995-01-31
ATE175445T1 (de) 1999-01-15
DK0864649T3 (da) 2006-08-28
DE69133525T8 (de) 2007-03-08
DE69133525D1 (de) 2006-06-01
AU8557491A (en) 1992-04-30
DE69130724D1 (de) 1999-02-18
EP0480525A2 (en) 1992-04-15
JP3242640B2 (ja) 2001-12-25
ATE324451T1 (de) 2006-05-15
DE69130724T2 (de) 1999-06-17
EP0480525A3 (en) 1992-09-30
ES2129025T3 (es) 1999-06-01
DK0480525T3 (da) 1999-08-30
EP0480525B1 (en) 1999-01-07
ES2264183T3 (es) 2006-12-16
EP0864649A3 (en) 1998-11-11
JP3189212B2 (ja) 2001-07-16
AU649482B2 (en) 1994-05-26
JP2001231582A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
HK1003032A1 (en) Novel antigens and methods for their preparation
EP0271302A3 (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
ATE59409T1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
GR3029582T3 (en) Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B)
IE873314L (en) T cell epitopes of the hepatitis b virus nucleocapsid¹protein
HK1012405A1 (en) Hybrid protein between cs from plasmodium and hbsag
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
HU9302285D0 (en) Method for producing recombinant adeno-virus vaccines
PT73021A (en) Process for producing dna sequences of recombinant dna molecules and polipeptides with specificyty on foot mouth disease as viral antigens
EP0250253A3 (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
EP0198299A3 (en) A process for preparing hepatitis b surface antigen containing particles in novel forms which are highly immunogenic
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
ES8505820A1 (es) Un procedimiento para producir una vacuna que previene la infeccion de hepatitis b
HU9302091D0 (en) Method for producing anti-viral vaccine against rabies
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
HK1009934A1 (en) Recombinant adenovirus vaccines
DE69128547D1 (de) Verfahren zur Herstellung von kondensierten Alkoholen mit einem Alkoxidkatalysator
ZA792485B (en) Vaccine for active immunization containing hepatitis b surface and/or e-antigens
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
EP0293201A3 (en) Method of vaccination for hepatitis b virus
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
DE3750330D1 (de) Verfahren zur Herstellung eines Impfstoffs gegen Hepatitis B.
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis